HUE056743T2 - 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureát tartalmazó vizes gyógyszerkészítmény - Google Patents

1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureát tartalmazó vizes gyógyszerkészítmény

Info

Publication number
HUE056743T2
HUE056743T2 HUE18769793A HUE18769793A HUE056743T2 HU E056743 T2 HUE056743 T2 HU E056743T2 HU E18769793 A HUE18769793 A HU E18769793A HU E18769793 A HUE18769793 A HU E18769793A HU E056743 T2 HUE056743 T2 HU E056743T2
Authority
HU
Hungary
Prior art keywords
phenyl
dimorpholin
triazin
piperidin
dimethylamino
Prior art date
Application number
HUE18769793A
Other languages
English (en)
Inventor
James Joseph Hussey
Andrew Gilbert Bright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HUE056743T2 publication Critical patent/HUE056743T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE18769793A 2017-08-25 2018-08-20 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureát tartalmazó vizes gyógyszerkészítmény HUE056743T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550007P 2017-08-25 2017-08-25
US201862681720P 2018-06-07 2018-06-07
US201862703022P 2018-07-25 2018-07-25

Publications (1)

Publication Number Publication Date
HUE056743T2 true HUE056743T2 (hu) 2022-03-28

Family

ID=63586769

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18769793A HUE056743T2 (hu) 2017-08-25 2018-08-20 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureát tartalmazó vizes gyógyszerkészítmény

Country Status (14)

Country Link
US (2) US11541058B2 (hu)
EP (1) EP3672571B1 (hu)
JP (1) JP7313126B2 (hu)
CY (1) CY1124820T1 (hu)
ES (1) ES2895370T3 (hu)
HR (1) HRP20211985T1 (hu)
HU (1) HUE056743T2 (hu)
LT (1) LT3672571T (hu)
PL (1) PL3672571T3 (hu)
PT (1) PT3672571T (hu)
RS (1) RS62663B1 (hu)
SI (1) SI3672571T1 (hu)
TW (1) TW201919635A (hu)
WO (1) WO2019038657A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230142810A (ko) * 2018-06-07 2023-10-11 화이자 인코포레이티드 1-(4-｛[4-(디메틸아미노)피페리딘-1-일]카르보닐｝페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아를 포함하는 수성 제제
IL310243A (en) 2021-07-26 2024-03-01 Celcuity Inc 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORHOLIN-4-YL-1,3,5-TRIAZIN-2-YL )PHENYL]urea (GEDATOLISIB) and its combinations for use in cancer treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
CA2472342A1 (en) 2002-01-30 2003-08-07 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
US10022381B2 (en) 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
SI3216793T1 (sl) 2008-05-23 2019-06-28 Wyeth Llc Triazinske sestavine kot zaviralci P13 KINAZE in MTOR
WO2010096619A1 (en) 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
US20140220112A1 (en) 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
PL3116547T3 (pl) 2014-03-14 2019-11-29 Pfizer Terapeutyczne nanocząstki zawierające środek terapeutyczny i sposoby ich wytwarzania i zastosowania
SI3233054T1 (sl) 2014-12-17 2021-11-30 Pfizer Inc. Formulacije zaviralca PI3k/mTOR za intravensko dajanje
KR20230142810A (ko) 2018-06-07 2023-10-11 화이자 인코포레이티드 1-(4-｛[4-(디메틸아미노)피페리딘-1-일]카르보닐｝페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아를 포함하는 수성 제제

Also Published As

Publication number Publication date
US20230218628A1 (en) 2023-07-13
EP3672571A1 (en) 2020-07-01
EP3672571B1 (en) 2021-10-06
JP2019038799A (ja) 2019-03-14
HRP20211985T1 (hr) 2022-04-01
US20210267988A1 (en) 2021-09-02
CY1124820T1 (el) 2022-11-25
RS62663B1 (sr) 2021-12-31
PL3672571T3 (pl) 2022-01-31
LT3672571T (lt) 2021-12-10
WO2019038657A1 (en) 2019-02-28
SI3672571T1 (sl) 2022-01-31
PT3672571T (pt) 2021-11-02
TW201919635A (zh) 2019-06-01
JP7313126B2 (ja) 2023-07-24
US11541058B2 (en) 2023-01-03
ES2895370T3 (es) 2022-02-21

Similar Documents

Publication Publication Date Title
PH12016501794A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
IL252368B (en) 2-(5,1-dimethyl-3-phenyl-h1-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- Oxacetamide and pharmaceutical preparations containing it
IL246545B (en) History of 3-hydroxy-3-[(cyclopropylmethoxy)-4-(fluoro)phenyl]-4-(h1- 3,2,1-triazol-1-yl)-butane and pharmaceutical preparations containing them
EP3626709A4 (en) INDAZOLE COMPOUND FOR USE IN INHIBITING KINASE ACTIVITY, COMPOSITION AND APPLICATION THEREOF
IL273573A (en) Nitrogen-containing heteroaryl compound and medicinal use thereof
IL279270A (en) Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
PL3103453T3 (pl) Kompozycja lecznicza zawierająca jako składnik czynny heterocykliczny związek diaminokarboksyamidowy
IL248773B (en) History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them
HRP20200104T8 (hr) Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto
CY1124527T1 (el) Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση
HUE056743T2 (hu) 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureát tartalmazó vizes gyógyszerkészítmény
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
IL243737B (en) History of -2amino-4-[3-(-7 fluoro-2-oxo-isoquinolin-1-yl)phenyl]-6-azoloamino-5,3,1-triazine and pharmaceutical preparations containing them
PL3024832T3 (pl) Pochodne 1-(piperazyn-1-ylo)-2-([1,2,4]triazol-1-ilo)-etanonu
PH12017502017A1 (en) Pharmaceutical compositions
IT201700098438A1 (it) Testiera per cavalli
UA37000S (uk) Диван кутовий «bruno»
EP3712149C0 (en) BENZAMIDE DERIVATIVE COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF AN INFLAMMATORY DISEASE USING THIS ACTIVE INGREDIENT
TH1601002081A (th) รูปแบบเภสัชภัณฑ์ซึ่งประกอบรวมด้วยโซเดียม 1-[6-(มอร์โฟลิน-4-อิล)ไพริมิดิน-4- อิล]-4-(1h-1,2,3-ไตรอะโซล-1-อิล)-1h-ไพราโซล-5-โอเลต
UA33872S (uk) Кутовий диван «renata»
UA35578S (uk) Кутовий диван «м1»
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid
TH168885A (th) อนุพันธ์ 1-(พิเพอราซิน-1-อิล)-2-([1,2,4]ไตรอะโซล-1-อิล)-เอทาโนน